HER2 Positive Breast Cancer: 138 Real Stories

138 stories match breast cancer and HER2 positive. 123 of them mention chemotherapy.

Cancer Stories

Kate, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Kate's Survivor Story

Patient Info: Kate Watson, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest lymph nodes; spine; pelvis; femur

As of October 2019, Kate had been in remission for about 3 years with regular PET scans showing no evidence of active disease, while continuing monthly HER2-targeted maintenance treatment.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurrence in the Parotid Gland Eight Years Later

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Primary breast tumor: ER-positive and HER2-positive. Parotid metastasis: ER-positive, PR-negative, and HER2-positive.

Metastatic Site: left parotid gland

The isolated parotid metastasis was completely resected, one-month PET-CT showed no significant abnormality, and endocrine therapy continued with exemestane.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Nocardia Infection Mimicked Breast Cancer Lung Metastases

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive.

The lung nodules resolved with antibiotics and proved infectious rather than metastatic; she remained in good health at the last follow-up in January 2019.

PubMed Central
OutcomeCancer-Free / NED
Jane, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Jane's Survivor Story

Patient Info: Jane Dennington, Female, 60s

Biomarkers: HER2-positive breast cancer

As of January 2019, Jane was cancer-free for almost 5 years after HER2-positive breast cancer treatment with chemotherapy, Herceptin, surgery and Kadcyla through the KATHERINE clinical trial.

Cleveland Clinic
OutcomeCancer-Free / NED
SI
Breast Cancer

Stage II HER2-Positive Breast Cancer With Anti-Yo Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: HER2 positive

Her severe anti-Yo paraneoplastic cerebellar syndrome did not meaningfully respond to IVIG or cancer treatment. She became wheelchair-dependent and ultimately required long-term care, with only moderate improvement in ataxia after rehabilitation.

PubMed Central
OutcomeNot reported
Ashley, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III BRCA2 Breast Cancer: Ashley's Survivor Story

Patient Info: Ashley, female, Under 40 | Stage III

Biomarkers: BRCA2 positive; HER2 positive

Ashley described herself as cancer-free after chemotherapy, double mastectomy and 30 rounds of radiation, with 10 months of Herceptin planned.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV Breast Cancer With Long-Term Tumor Regression After Radiation Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2 positive

Metastatic Site: 8th thoracic vertebra

Follow-up showed near-complete regression of the breast tumor, resolution of the bone lesion, normal tumor markers, and a 2015 biopsy with no tumor cells. Follow-up showed no further recurrence, and she returned to work with good quality of life.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed Central
OutcomeCare Ongoing
Sarah, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Sarah's Patient Story

Patient Info: Sarah, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; BRCA and other known hereditary breast cancer genes not identified in family history discussion

As of January 2017, Sarah had been living for almost 3 years with recurrent Stage IV HER2-positive breast cancer and was receiving Kadcyla every 3 weeks.

YouTube — Oncology Associates
OutcomeLiving With Cancer
HR
Breast Cancer

HER2-Positive Right Breast Cancer With Complete Response Before Bilateral Mastectomy

Patient Info: Anonymized, female, 50s

Biomarkers: ER negative, PR negative, HER2 positive

After neoadjuvant treatment, imaging showed complete resolution of the right-breast mass and mastectomy pathology found no residual right-breast tumor or malignant right sentinel node.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with isolated adrenal metastasis: adrenalectomy with no recurrence at follow-up

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Primary breast tumor and adrenal metastasis were HER2-positive and ER/PR negative; adrenal markers supported breast origin.

Metastatic Site: left adrenal gland

Alive in good condition with no evidence of recurrence more than 3 years after adrenalectomy for isolated adrenal metastasis and more than 5 years after the original breast surgery.

PubMed Central
OutcomeCancer-Free / NED